COVID-19 Group Testing Method Delivers Results 13 Times Faster than Individual Testing of Each Sample
|
By LabMedica International staff writers Posted on 30 Mar 2021 |

Illustration
A new group method of testing for COVID-19 allows results to be obtained 13 times faster as compared to individual testing of each sample.
The new method developed by researchers from the HSE Laboratory of Algorithms and Technologies for Networks Analysis (Nizhny Novgorod, Russia) and Vilnius University (Vilnius, Lithuania) can be used for asymptomatic populations with seemingly low incidence of coronavirus cases, where it will help detect the infected individuals at a maximum speed with a minimum number of tests, and timely apply the quarantine measures in order to prevent spreading of the disease.
Present COVID-19 testing solutions are based on the extraction of RNA from patients using oropharyngeal and nasopharyngeal swabs, and then testing with real-time PCR for the presence of specific RNA filaments identifying the virus. The speed of this approach is limited by the availability of reactants, trained technicians and laboratories. One way to speed up the testing procedures is group testing, where the swabs of multiple patients are grouped together and tested. The swabs from groups that return a positive result are then tested individually in order to detect specific COVID-19 positive patients. This approach helps decrease the number of tests twofold or more (depending on the spread of the disease) as compared to individual testing of each swab.
For example, suppose 96 samples should be tested and pools of up to 12 samples are possible. In individual testing, 96 tests are necessary. In pool testing, 8 pools of 12 samples are taken and testing is performed. If the result of one pool is positive, then additional 12 individual tests are needed. If two or three groups return a positive result, 24 or 36 additional tests are required, which, together with the first eight tests, will mean a decrease in the number of tests from two to five times as compared to individual testing. The researchers believe that the number of tests can be decreased by optimizing the size of groups that takes into account the total number of swabs and the forecasted number of infected individuals. As the number of infected individuals increases, the possibility of saving swabs decreases but is still about 40% in the event of an incidence of 100 positive samples per 1,000, and 18% for an incidence of 200 per 1,000.
There are ways to optimize group testing, such as choosing the optimal group size based on the total number of swabs and the projected level of disease spreading. Another is the binary splitting method, in which a positive group is split into halves and is tested again, until individual positive swabs are detected. The second method, however, is very time-consuming, which decreases its attractiveness during a pandemic. In addition, to optimize group testing, transposition-based replication is used: after grouping the swabs, researchers form additional control groups from the same swabs and test them together with the main groups. This helps further cut the number of tests, and if the disease levels are low, it also helps to detect positive swabs in one step, which speeds up the testing considerably.
However, this method does not allow for experimenting with group sizes to detect the optimal group size under specific conditions. Researchers from HSE University and Vilnius University suggested OptReplica technology, which uses a more complicated algorithm of swab grouping in key and control groups and helps decrease the number of control groups. In addition, the algorithm helps calculate the optimal group size for the present number of swabs and the forecasted level of disease spreading. The researchers conducted experimental research on samples of 96 and 384 swabs, carrying out 100 randomized tests for each sample size, and compared the effectiveness of transposition-based replication and OptReplica method for different levels of disease incidence. The studies have shown that if the optimal size of groups is chosen, OptReplica is more effective than transposition-based replication. In cases with low incidence, the use of OptReplica, a 13x average reduction of tests can be achieved compared to individual testing without time delay.
“Our simulations are actually proving that using this optimization replication strategy is always advantageous and, even in case of high spread of the disease (10% or 20% of positives in the population), we are still competitive with individual testing strategy,” explained Mario Guarracino, Chief Research Fellow of the Laboratory of Algorithms and Technologies for Networks Analysis.
Related Links:
HSE Laboratory of Algorithms and Technologies for Networks Analysis
Vilnius University
The new method developed by researchers from the HSE Laboratory of Algorithms and Technologies for Networks Analysis (Nizhny Novgorod, Russia) and Vilnius University (Vilnius, Lithuania) can be used for asymptomatic populations with seemingly low incidence of coronavirus cases, where it will help detect the infected individuals at a maximum speed with a minimum number of tests, and timely apply the quarantine measures in order to prevent spreading of the disease.
Present COVID-19 testing solutions are based on the extraction of RNA from patients using oropharyngeal and nasopharyngeal swabs, and then testing with real-time PCR for the presence of specific RNA filaments identifying the virus. The speed of this approach is limited by the availability of reactants, trained technicians and laboratories. One way to speed up the testing procedures is group testing, where the swabs of multiple patients are grouped together and tested. The swabs from groups that return a positive result are then tested individually in order to detect specific COVID-19 positive patients. This approach helps decrease the number of tests twofold or more (depending on the spread of the disease) as compared to individual testing of each swab.
For example, suppose 96 samples should be tested and pools of up to 12 samples are possible. In individual testing, 96 tests are necessary. In pool testing, 8 pools of 12 samples are taken and testing is performed. If the result of one pool is positive, then additional 12 individual tests are needed. If two or three groups return a positive result, 24 or 36 additional tests are required, which, together with the first eight tests, will mean a decrease in the number of tests from two to five times as compared to individual testing. The researchers believe that the number of tests can be decreased by optimizing the size of groups that takes into account the total number of swabs and the forecasted number of infected individuals. As the number of infected individuals increases, the possibility of saving swabs decreases but is still about 40% in the event of an incidence of 100 positive samples per 1,000, and 18% for an incidence of 200 per 1,000.
There are ways to optimize group testing, such as choosing the optimal group size based on the total number of swabs and the projected level of disease spreading. Another is the binary splitting method, in which a positive group is split into halves and is tested again, until individual positive swabs are detected. The second method, however, is very time-consuming, which decreases its attractiveness during a pandemic. In addition, to optimize group testing, transposition-based replication is used: after grouping the swabs, researchers form additional control groups from the same swabs and test them together with the main groups. This helps further cut the number of tests, and if the disease levels are low, it also helps to detect positive swabs in one step, which speeds up the testing considerably.
However, this method does not allow for experimenting with group sizes to detect the optimal group size under specific conditions. Researchers from HSE University and Vilnius University suggested OptReplica technology, which uses a more complicated algorithm of swab grouping in key and control groups and helps decrease the number of control groups. In addition, the algorithm helps calculate the optimal group size for the present number of swabs and the forecasted level of disease spreading. The researchers conducted experimental research on samples of 96 and 384 swabs, carrying out 100 randomized tests for each sample size, and compared the effectiveness of transposition-based replication and OptReplica method for different levels of disease incidence. The studies have shown that if the optimal size of groups is chosen, OptReplica is more effective than transposition-based replication. In cases with low incidence, the use of OptReplica, a 13x average reduction of tests can be achieved compared to individual testing without time delay.
“Our simulations are actually proving that using this optimization replication strategy is always advantageous and, even in case of high spread of the disease (10% or 20% of positives in the population), we are still competitive with individual testing strategy,” explained Mario Guarracino, Chief Research Fellow of the Laboratory of Algorithms and Technologies for Networks Analysis.
Related Links:
HSE Laboratory of Algorithms and Technologies for Networks Analysis
Vilnius University
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
Early and accurate identification of Alzheimer’s disease remains challenging in routine care, particularly outside memory clinics. Confirmation often depends on positron emission tomography (PET) imaging... Read more
New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
Alamar Biosciences (Fremont, CA, USA) has introduced the first commercial immunoassay for enhanced microtubule binding region tau (eMTBR-Tau). The assay is available within the NULISAseq Neuro 220 multiplexed... Read moreMolecular Diagnostics
view channel
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more
Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
Many adults inherit genetic changes that increase their risk for cancer and cardiovascular disease, yet access to testing often remains concentrated in large medical centers. Reaching rural and socially... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Frailty in older adults is marked by increased vulnerability to disease, falls, functional decline, and death, yet its biological drivers remain incompletely understood. Because the gut microbiota influences... Read morePathology
view channel
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read more
Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
Colorectal cancer remains a leading cause of cancer mortality, and many patients relapse despite apparently successful surgery and chemotherapy. Detecting minimal disease that persists after treatment... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more









